Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

T Cell Proliferative Responses and IgG Antibodies to β2GPI in Patients with Diabetes and Atherosclerosis

Author(s): Mohammad R. Monjezi, Hamed Fouladseresht, Shirin Farjadian, Behrouz Gharesi-Fard, Shahdad Khosropanah and Mehrnoosh Doroudchi*

Volume 21, Issue 3, 2021

Published on: 05 May, 2020

Page: [495 - 503] Pages: 9

DOI: 10.2174/1871530320666200505115850

Price: $65

Abstract

Background: Diabetes increases the risk of myocardial infarction (MI) by 2 to 3 folds. Tlymphocytes play a role in atherosclerosis, which is the main pathology behind MI. Cellular immune responses to beta-2 glycoprotein I (β2GPI) are shown in carotid atherosclerosis.

Objective: To investigate the self-reactive, β2GPI-specific T-lymphocytes in patients with and without diabetes and atherosclerosis.

Methods: Collectively, 164 subjects with and without diabetes that underwent coronary angiography were divided into four groups based on their diabetes status and coronary stenosis. Group I=Diabetic with ≥50% stenosis: A+D+ (n=66); Group II=Non-diabetic with ≥50% stenosis, A+D- (n=39); Group III=Diabetic with <50% stenosis: A-D+ (n=28); and Group IV=Non-diabetic with <50% stenosis: AD- (n=31). All groups were evaluated for anti-β2GPI IgG antibody by ELISA method. Then, PBMCs were isolated from 18 subjects and were stimulated with β2GPI-derived peptides to assess their proliferation in accordance with their HLA-DRB1 alleles.

Results: Mean β2GPI IgG levels were higher in groups with ≥50% stenosis (A+) compared to those with <50% stenosis (A-), (P=0.02). The co-presence of diabetes in A+ individuals increased mean β2GPI-specific IgG. Auto-reactive β2GPI-specific T cells were detected in the repertoire of T-lymphocytes in all groups. β2GPI-peptides showed promiscuous restriction by various HLADRB1.

Conclusion: β2GPI is the target of cellular and humoral immune responses in patients with atherosclerosis. Since the T cell responses but not antibodies were detectable in A-D+ and A-D- groups, it is reasonable to assume that cellular responses preceded the humoral responses. Post-translation modifications of β2GPI under oxidative and glycemic stresses may have increased the IgG levels in patients with diabetes. Finally, identification of antigens that trigger immuno-pathogenesis in atherosclerosis and diabetes may help the development of immunomodulation methods to prevent or treat these debilitating diseases.

Keywords: Diabetes mellitus, atherosclerosis, CFSE dilution assay, HLA-DRB1, immunoglobulin G, beta 2-Glycoprotein I.

« Previous Next »
Graphical Abstract

[1]
Skyler, J.S.; Bergenstal, R.; Bonow, R.O.; Buse, J.; Deedwania, P.; Gale, E.A.; Howard, B.V.; Kirkman, M.S.; Kosiborod, M.; Reaven, P.; Sherwin, R.S. American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. J. Am. Coll. Cardiol., 2009, 53(3), 298-304.
[http://dx.doi.org/10.1016/j.jacc.2008.10.008] [PMID: 19147051]
[2]
Association, A.D. American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care, 2014, 37(Suppl. 1), S14-S80.
[http://dx.doi.org/10.2337/dc14-S014] [PMID: 24357209]
[3]
Shore, A.C.; Colhoun, H.M.; Natali, A.; Palombo, C.; Östling, G.; Aizawa, K.; Kennbäck, C.; Casanova, F.; Persson, M.; Gooding, K.; Gates, P.E.; Khan, F.; Looker, H.C.; Adams, F.; Belch, J.; Pinnoli, S.; Venturi, E.; Morizzo, C.; Goncalves, I.; Ladenvall, C.; Nilsson, J. SUMMIT consortium. Measures of atherosclerotic burden are associated with clinically manifest cardiovascular disease in type 2 diabetes: a European cross-sectional study. J. Intern. Med., 2015, 278(3), 291-302.
[http://dx.doi.org/10.1111/joim.12359] [PMID: 25752315]
[4]
Domingueti, C.P.; Dusse, L.M.S.A.; Carvalho, Md.; de Sousa, L.P.; Gomes, K.B.; Fernandes, A.P. Diabetes mellitus: the linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. J. Diabetes Complications, 2016, 30(4), 738-745.
[http://dx.doi.org/10.1016/j.jdiacomp.2015.12.018] [PMID: 26781070]
[5]
Natali, A.; Vichi, S.; Landi, P.; Severi, S.; L’Abbate, A.; Ferrannini, E. Coronary atherosclerosis in type II diabetes: angiographic findings and clinical outcome. Diabetologia, 2000, 43(5), 632-641.
[http://dx.doi.org/10.1007/s001250051352] [PMID: 10855538]
[6]
Lam, D.W.; LeRoith, D. The worldwide diabetes epidemic. Curr. Opin. Endocrinol. Diabetes Obes., 2012, 19(2), 93-96.
[http://dx.doi.org/10.1097/MED.0b013e328350583a] [PMID: 22262000]
[7]
IDF Diabetes Atlas Group. Update of mortality attributable to diabetes for the IDF diabetes atlas: estimates for the year 2013. Diabetes Res. Clin. Pract., 2015, 109(3), 461-465.
[http://dx.doi.org/10.1016/j.diabres.2015.05.037] [PMID: 26119773]
[8]
Roma-Lavisse, C.; Tagzirt, M.; Zawadzki, C.; Lorenzi, R.; Vincentelli, A.; Haulon, S.; Juthier, F.; Rauch, A.; Corseaux, D.; Staels, B.; Jude, B.; Van Belle, E.; Susen, S.; Chinetti-Gbaguidi, G.; Dupont, A. M1 and M2 macrophage proteolytic and angiogenic profile analysis in atherosclerotic patients reveals a distinctive profile in type 2 diabetes. Diab. Vasc. Dis. Res., 2015, 12(4), 279-289.
[http://dx.doi.org/10.1177/1479164115582351] [PMID: 25966737]
[9]
Goncalves, I.; Bengtsson, E.; Colhoun, H.M.; Shore, A.C.; Palombo, C.; Natali, A.; Edsfeldt, A.; Dunér, P.; Fredrikson, G.N.; Björkbacka, H.; Östling, G.; Aizawa, K.; Casanova, F.; Persson, M.; Gooding, K.; Strain, D.; Khan, F.; Looker, H.C.; Adams, F.; Belch, J.; Pinnoli, S.; Venturi, E.; Kozakova, M.; Gan, L.M.; Schnecke, V.; Nilsson, J. SUMMIT Consortium. Elevated plasma levels of MMP-12 are associated with atherosclerotic burden and symptomatic cardiovascular disease in subjects with type 2 diabetes. Arterioscler. Thromb. Vasc. Biol., 2015, 35(7), 1723-1731.
[http://dx.doi.org/10.1161/ATVBAHA.115.305631] [PMID: 25953645]
[10]
Ionita, M.G.; Arslan, F.; de Kleijn, D.P.; Pasterkamp, G. Endogenous inflammatory molecules engage toll-like receptors in cardiovascular disease. J. Innate Immun., 2010, 2(4), 307-315.
[http://dx.doi.org/10.1159/000314270] [PMID: 20431283]
[11]
George, J.; Harats, D.; Gilburd, B.; Afek, A.; Shaish, A.; Kopolovic, J.; Shoenfeld, Y. Adoptive transfer of β(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation, 2000, 102(15), 1822-1827.
[http://dx.doi.org/10.1161/01.CIR.102.15.1822] [PMID: 11023938]
[12]
Profumo, E.; Buttari, B.; Alessandri, C.; Conti, F.; Capoano, R.; Valesini, G.; Salvati, B.; Riganò, R. Beta2-glycoprotein I is a target of T cell reactivity in patients with advanced carotid atherosclerotic plaques. Int. J. Immunopathol. Pharmacol., 2010, 23(1), 73-80.
[http://dx.doi.org/10.1177/039463201002300107] [PMID: 20377996]
[13]
Walton, K.; Rowe, D.; Soothill, J. An investigation of methods of isolation of β2M1 globulin (Syn.: Iota Protein, 19S γ globulin, γ1 macroglobulin, β2M globulin) and its association with isoagglutinin activity, together with preliminary observations on other macroglobulins of slow electrophoretic mobility in normal human serum. Immunology, 1963, 6(4), 305-330.
[14]
Haupt, H.; Schwick, H.G.; Störiko, K. On a hereditary beta-2-glycoprotein I deficiency. Humangenetik, 1968, 5(4), 291-293.
[PMID: 5670607]
[15]
Berndt, C.; Lillig, C.H.; Holmgren, A. Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system. Am. J. Physiol. Heart Circ. Physiol., 2007, 292(3), H1227-H1236.
[http://dx.doi.org/10.1152/ajpheart.01162.2006] [PMID: 17172268]
[16]
Martínez-Ruiz, A.; Lamas, S. Signalling by NO-induced protein S-nitrosylation and S-glutathionylation: convergences and divergences. Cardiovasc. Res., 2007, 75(2), 220-228.
[http://dx.doi.org/10.1016/j.cardiores.2007.03.016] [PMID: 17451659]
[17]
Kurien, B.T.; Scofield, R.H. Autoimmunity and oxidatively modified autoantigens. Autoimmun. Rev., 2008, 7(7), 567-573.
[http://dx.doi.org/10.1016/j.autrev.2008.04.019] [PMID: 18625446]
[18]
Buttari, B.; Profumo, E.; Mattei, V.; Siracusano, A.; Ortona, E.; Margutti, P.; Salvati, B.; Sorice, M.; Riganò, R. Oxidized β2-glycoprotein I induces human dendritic cell maturation and promotes a T helper type 1 response. Blood, 2005, 106(12), 3880-3887.
[http://dx.doi.org/10.1182/blood-2005-03-1201] [PMID: 16099886]
[19]
Matsuura, E.; Kobayashi, K.; Inoue, K.; Lopez, L.R.; Shoenfeld, Y. Oxidized LDL/β2-glycoprotein I complexes: new aspects in atherosclerosis. Lupus, 2005, 14(9), 736-741.
[http://dx.doi.org/10.1191/0961203305lu2211oa] [PMID: 16218478]
[20]
Alves, J.D.; Grima, B. Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: a gateway to atherosclerosis. Curr. Rheumatol. Rep., 2003, 5(5), 383-390.
[http://dx.doi.org/10.1007/s11926-003-0029-1] [PMID: 12967525]
[21]
Ito, H.; Matsushita, S.; Tokano, Y.; Nishimura, H.; Tanaka, Y.; Fujisao, S.; Mitsuya, H.; Hashimoto, H.; Nishimura, Y. Analysis of T cell responses to the β 2-glycoprotein I-derived peptide library in patients with anti-β 2-glycoprotein I antibody-associated autoimmunity. Hum. Immunol., 2000, 61(4), 366-377.
[http://dx.doi.org/10.1016/S0198-8859(99)00184-6] [PMID: 10715514]
[22]
Kovjazin, R.; Carmon, L. The use of signal peptide domains as vaccine candidates. Hum. Vaccin. Immunother., 2014, 10(9), 2733-2740.
[http://dx.doi.org/10.4161/21645515.2014.970916] [PMID: 25483491]
[23]
Kovjazin, R.; Volovitz, I.; Daon, Y.; Vider-Shalit, T.; Azran, R.; Tsaban, L.; Carmon, L.; Louzoun, Y. Signal peptides and trans-membrane regions are broadly immunogenic and have high CD8+ T cell epitope densities: implications for vaccine development. Mol. Immunol., 2011, 48(8), 1009-1018.
[http://dx.doi.org/10.1016/j.molimm.2011.01.006] [PMID: 21316766]
[24]
Vita, R; Zarebski, L; Greenbaum, JA The immune epitope database 2.0. Nucleic Acids Res. Suppl., 2009, 38((suppl_1)), D854-D862.
[25]
Kovjazin, R.; Volovitz, I.; Kundel, Y.; Rosenbaum, E.; Medalia, G.; Horn, G.; Smorodinsky, N.I.; Brenner, B.; Carmon, L. ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors. Vaccine, 2011, 29(29-30), 4676-4686.
[http://dx.doi.org/10.1016/j.vaccine.2011.04.103] [PMID: 21570434]
[26]
Kovjazin, R.; Shitrit, D.; Preiss, R. Characterization of novel multi-antigenic vaccine candidates with pan-HLA coverage against M. tuberculosis. Clin. Vaccine Immunol., 2013, CVI, 00586-12.
[27]
Carmon, L.; Avivi, I.; Kovjazin, R.; Zuckerman, T.; Dray, L.; Gatt, M.E.; Or, R.; Shapira, M.Y. Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients. Br. J. Haematol., 2015, 169(1), 44-56.
[http://dx.doi.org/10.1111/bjh.13245] [PMID: 25496030]
[28]
Kronenberg, D.; Knight, R.R.; Estorninho, M.; Ellis, R.J.; Kester, M.G.; de Ru, A.; Eichmann, M.; Huang, G.C.; Powrie, J.; Dayan, C.M.; Skowera, A.; van Veelen, P.A.; Peakman, M. Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill β-cells. Diabetes, 2012, 61(7), 1752-1759.
[http://dx.doi.org/10.2337/db11-1520] [PMID: 22522618]
[29]
Kerzerho, J; Schneider, A; Favry, E The signal peptide of the tumor-shared antigen midkine hosts CD4+ T cell epitopes. jbc, 2013, M112-427302.
[30]
Kerzerho, J.; Adotevi, O.; Castelli, F.A. The angiogenic growth factor and biomarker midkine is a tumor-shared antigen. J. Immunol., 2010, 185(1), 418-423.
[http://dx.doi.org/10.4049/jimmunol.0901014] [PMID: 20511550]
[31]
Marchand, M.; van Baren, N.; Weynants, P.; Brichard, V.; Dréno, B.; Tessier, M.H.; Rankin, E.; Parmiani, G.; Arienti, F.; Humblet, Y.; Bourlond, A.; Vanwijck, R.; Liénard, D.; Beauduin, M.; Dietrich, P.Y.; Russo, V.; Kerger, J.; Masucci, G.; Jäger, E.; De Greve, J.; Atzpodien, J.; Brasseur, F.; Coulie, P.G.; van der Bruggen, P.; Boon, T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer, 1999, 80(2), 219-230.
[http://dx.doi.org/10.1002/(SICI)1097-0215(19990118)80:2<219:AID-IJC10>3.0.CO;2-S] [PMID: 9935203]
[32]
Martoglio, B.; Dobberstein, B. Signal sequences: more than just greasy peptides. Trends Cell Biol., 1998, 8(10), 410-415.
[http://dx.doi.org/10.1016/S0962-8924(98)01360-9] [PMID: 9789330]
[33]
von Heijne, G. The signal peptide. J. Membr. Biol., 1990, 115(3), 195-201.
[http://dx.doi.org/10.1007/BF01868635] [PMID: 2197415]
[34]
Kalies, K-U.; Görlich, D.; Rapoport, T.A. Binding of ribosomes to the rough endoplasmic reticulum mediated by the Sec61p-complex. J. Cell Biol., 1994, 126(4), 925-934.
[http://dx.doi.org/10.1083/jcb.126.4.925] [PMID: 8051212]
[35]
Zehner, M.; Marschall, A.L.; Bos, E.; Schloetel, J.G.; Kreer, C.; Fehrenschild, D.; Limmer, A.; Ossendorp, F.; Lang, T.; Koster, A.J.; Dübel, S.; Burgdorf, S. The translocon protein Sec61 mediates antigen transport from endosomes in the cytosol for cross-presentation to CD8(+) T cells. Immunity, 2015, 42(5), 850-863.
[http://dx.doi.org/10.1016/j.immuni.2015.04.008] [PMID: 25979419]
[36]
Beckmann, R.; Bubeck, D.; Grassucci, R.; Penczek, P.; Verschoor, A.; Blobel, G.; Frank, J. Alignment of conduits for the nascent polypeptide chain in the ribosome-Sec61 complex. Science, 1997, 278(5346), 2123-2126.
[http://dx.doi.org/10.1126/science.278.5346.2123] [PMID: 9405348]
[37]
Hanein, D.; Matlack, K.E.; Jungnickel, B.; Plath, K.; Kalies, K.U.; Miller, K.R.; Rapoport, T.A.; Akey, C.W. Oligomeric rings of the Sec61p complex induced by ligands required for protein translocation. Cell, 1996, 87(4), 721-732.
[http://dx.doi.org/10.1016/S0092-8674(00)81391-4] [PMID: 8929540]
[38]
Aichinger, G.; Karlsson, L.; Jackson, M.R.; Vestberg, M.; Vaughan, J.H.; Teyton, L.; Lechler, R.I.; Peterson, P.A. Major histocompatibility complex class II-dependent unfolding, transport, and degradation of endogenous proteins. J. Biol. Chem., 1997, 272(46), 29127-29136.
[http://dx.doi.org/10.1074/jbc.272.46.29127] [PMID: 9360989]
[39]
Kuwana, M. β2-glycoprotein I: antiphospholipid syndrome and T-cell reactivity. Thromb. Res., 2004, 114(5-6), 347-355.
[http://dx.doi.org/10.1016/j.thromres.2004.06.029] [PMID: 15507264]
[40]
Bouneaud, C.; Kourilsky, P.; Bousso, P. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity, 2000, 13(6), 829-840.
[http://dx.doi.org/10.1016/S1074-7613(00)00080-7] [PMID: 11163198]
[41]
Wolkers, M.C.; Brouwenstijn, N.; Bakker, A.H.; Toebes, M.; Schumacher, T.N. Antigen bias in T cell cross-priming. Science, 2004, 304(5675), 1314-1317.
[http://dx.doi.org/10.1126/science.1096268] [PMID: 15166378]
[42]
Veas, F. Acute phase proteins as early non-specific biomarkers of human and veterinary diseases; BoD–Books on Demand, 2011.
[http://dx.doi.org/10.5772/1045]
[43]
Castro, A.; Lázaro, I.; Selva, D.M.; Céspedes, E.; Girona, J. NúriaPlana; Guardiola, M.; Cabré, A.; Simó, R.; Masana, L. APOH is increased in the plasma and liver of type 2 diabetic patients with metabolic syndrome. Atherosclerosis, 2010, 209(1), 201-205.
[http://dx.doi.org/10.1016/j.atherosclerosis.2009.09.072] [PMID: 19878946]
[44]
Marrack, P.; Kappler, J.W. Do MHCII-presented neoantigens drive type 1 diabetes and other autoimmune diseases? Cold Spring Harb. Perspect. Med., 2012, 2(9), a007765.
[http://dx.doi.org/10.1101/cshperspect.a007765 ] [PMID: 22951444]

Rights & Permissions Print Cite
Article Metrics
11
1
© 2024 Bentham Science Publishers | Privacy Policy